Market Place
Sourcing Support
All News #Library
Biotech
MapLight Therapeutics Completes ZEPHYR Phase 2 Enrollment
01 May 2026 //
FIRSTWORD PHARMA
Maplight Therapeutics To Join Investor Conference
02 Mar 2026 //
GLOBENEWSWIRE
Maplight Therapeutics Shifts Phase 2 Study Results Timing To Q3
09 Jan 2026 //
GLOBENEWSWIRE
Maplight Therapeutics Gets Fast Track For ML-007C-MA
05 Jan 2026 //
GLOBENEWSWIRE
SandboxAQ & MapLight Announce Collaboration to Novel CNS Therapy
16 Dec 2025 //
GLOBENEWSWIRE
MapLight Therapeutics Reports Q3 Results, Progress
04 Dec 2025 //
GLOBENEWSWIRE
Maplight Therapeutics Completes IPO With Full Underwriters Option
29 Oct 2025 //
GLOBENEWSWIRE
Maplight Goes Public Via $250M IPO To Fund Cobenfy Competitor
27 Oct 2025 //
FIERCE BIOTECH
Maplight Therapeutics Prices IPO
26 Oct 2025 //
GLOBENEWSWIRE
Maplight Illuminates $262M IPO Plans To Fund Cobenfy Competitor
07 Oct 2025 //
FIERCE BIOTECH
Maplight Therapeutics Initiates IPO Launch
06 Oct 2025 //
PR NEWSWIRE
MapLight raises $373M to Plot Phase 2 journey for Cobenfy rival
29 Jul 2025 //
FIERCE BIOTECH
MapLight Therapeutics Secures $372.5M in Series D Funding
28 Jul 2025 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.